41 results
8-K
EX-99.1
RNAC
Cartesian Therapeutics Inc
31 Oct 23
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
4:06pm
as a consultant to Sobi, helping to oversee the clinical and regulatory activities associated with SEL-212. Dr. Traber will also continue to serve in his role
DEFR14A
moqu4m9g2nzmb8n0mr
3 May 22
Revised proxy
2:15pm
PRE 14A
jz5ac46xfgnq
22 Apr 22
Preliminary proxy
3:08pm
8-K
EX-10.1.1
i3tx54 54xjn0jz07hkd
3 Sep 20
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-99.1
qir7 l17rfjvpu2hg07c
6 Aug 20
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
8:00am